Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Paul Dorman, Curtis Lockshin


RXi Pharmaceuticals has appointed Paul Dorman and Curtis Lockshin to its board of directors.

Dorman is currently chairman and CEO of holding company DFB Pharmaceuticals, and he holds a BS in mechanical engineering from Tulane University and a JD from Loyola University.

Lockshin most recently served as an independent consultant to Opko Health, which recently sold its RNAi assets to RXi. Before that, he was vice president of corporate research and development initiatives for Opko.